Venetoclax and Blinatumomab for adult patients with relapsed/refractory or MRD positive Ph-negative B-cell precursor ALL: phase I part of the GMALL-BLIVEN trial.
Saved in:
| Title: | Venetoclax and Blinatumomab for adult patients with relapsed/refractory or MRD positive Ph-negative B-cell precursor ALL: phase I part of the GMALL-BLIVEN trial. |
|---|---|
| Authors: | Fransecky L; Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. lars.fransecky@uksh.de.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany. lars.fransecky@uksh.de., Fiedler W; Department of Oncology and Hematology with Section Pneumology, University Medical Center Hamburg-Eppendorf, University Cancer Center Hamburg, Hamburg, Germany., Röllig C; Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany., Sauer T; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany., Raffel S; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany., Alsdorf W; Department of Oncology and Hematology with Section Pneumology, University Medical Center Hamburg-Eppendorf, University Cancer Center Hamburg, Hamburg, Germany., Heberling L; Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany., Steer B; Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany., Huber K; Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany.; Clinical Research Unit 'CATCH ALL' (KFO 5010) funded by the Deutsche Forschungsgemeinschaft, Bonn, Germany., Versteegen T; Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany., Spory L; Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany., Deckbar D; Department of Internal Medicine II, Hematology and Oncology, Goethe University Hospital Frankfurt, Frankfurt, Germany., Reiser L; Department of Internal Medicine II, Hematology and Oncology, Goethe University Hospital Frankfurt, Frankfurt, Germany., Bendig S; Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany.; Clinical Research Unit 'CATCH ALL' (KFO 5010) funded by the Deutsche Forschungsgemeinschaft, Bonn, Germany., Bastian L; Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany.; Clinical Research Unit 'CATCH ALL' (KFO 5010) funded by the Deutsche Forschungsgemeinschaft, Bonn, Germany., Bozzetti C; Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany., Beder T; Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany., Neumann M; Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany.; Clinical Research Unit 'CATCH ALL' (KFO 5010) funded by the Deutsche Forschungsgemeinschaft, Bonn, Germany., Brüggemann M; Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany.; Clinical Research Unit 'CATCH ALL' (KFO 5010) funded by the Deutsche Forschungsgemeinschaft, Bonn, Germany., Gökbuget N; Department of Internal Medicine II, Hematology and Oncology, Goethe University Hospital Frankfurt, Frankfurt, Germany., Baldus C; Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany.; Clinical Research Unit 'CATCH ALL' (KFO 5010) funded by the Deutsche Forschungsgemeinschaft, Bonn, Germany. |
| Source: | Annals of hematology [Ann Hematol] 2026 Feb 12; Vol. 105 (3), pp. 109. Date of Electronic Publication: 2026 Feb 12. |
| Publication Type: | Journal Article; Clinical Trial, Phase I; Multicenter Study |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0584 (Electronic) Linking ISSN: 09395555 NLM ISO Abbreviation: Ann Hematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1432-0584 |
|---|---|
| DOI: | 10.1007/s00277-026-06883-8 |
